North America Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The Report Covers North America Human Insulin Market Trends & Analysis. The Market is Segmented by Drug (basal or Long-Acting Insulin, Bolus or Fast-Acting Insulin, Traditional Human Insulin, Combination Insulin, And Biosimilar Insulin) and Geography (United States, Canada, And Rest of North America). The Value is Provided (in USD) and Volume (in Units) for the Above Segments.

North America Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

North America Insulin Industry Overview

The North American human insulin market is highly fragmented, with three major manufacturers having a large market share. In the United States, there are no other players except Novo Nordisk, Sanofi, and Eli Lilly. In the remaining countries, the manufacturers confine themselves to other local or region-specific manufacturers. Mergers and acquisitions that happened between the players in the recent past helped the companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Basaglar (insulin glargine).

North America Insulin Market Leaders

  1. Sanofi S.A.

  2. Novo Nordisk A/S

  3. Eli Lilly and Company

  4. Pfizer Inc

  5. Biocon Limited

  6. *Disclaimer: Major Players sorted in no particular order
North America Human Insulin Drugs Market Concentration

North America Insulin Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?